What is BPC-157?

BPC-157 has become the most talked-about compound in the research-peptide world. It is discussed on podcasts, sold by online vendors, and credited with everything from tendon repair to gut healing. Stripped of the noise, the honest position is narrower — and more interesting — than either the enthusiasts or the sceptics will tell you.

What it actually is

BPC-157 — "body protection compound 157" — is a synthetic peptide of fifteen amino acids, named by its developers, a Croatian research group led by Predrag Sikiric at the University of Zagreb. It was originally identified as a fragment of a larger protein found in human gastric juice; the synthetic sequence sold today is loosely related to a small portion of that protein. It belongs to the category the book calls the unregulated market: compounds sold "research use only" that are not approved as medicines for human use.

That regulatory status is the single most important fact about it, and it is the one most often skipped over in the marketing.

What the research actually shows

This is, in many ways, the central issue with BPC-157: the literature is large in paper count but narrow in source. A 2025 systematic review by Vasireddi and colleagues in the American Journal of Sports Medicine screened 544 articles on BPC-157 in orthopaedic applications and found only one that was a clinical study. The other 35 included studies were preclinical animal models. The reviewers noted that despite its popularity and wide availability through non-regulated sources, there is minimal human data available.

The animal data is also disproportionately produced by a single research group, with limited independent replication. So the honest picture is three things at once: the preclinical biology is genuinely interesting, the gap between that biology and any human clinical evidence is enormous, and what little short-term human safety data exists comes from very small studies that fall far short of what would support approval as a medicine.

Where it stands with regulators

BPC-157 is not an approved medicine anywhere. The FDA has not approved it for any indication; it was placed in Category 2 of the bulk drug substances list in 2023 and removed in April 2026 — a procedural reclassification that does not amount to approval. In the UK, the MHRA does not license it, and supply for human use is unlawful under medicines legislation. It is not licensed by the EMA. The World Anti-Doping Agency has listed it as a prohibited substance since 2022.

The contamination problem compounds the uncertainty. Independent testing of products labelled as BPC-157 has at times found different compounds, no detectable active ingredient, or significant impurities.

The sober bottom line

BPC-157 is neither the miracle of the marketing nor a pure scam. As the book puts it, it is a compound with an interesting preclinical biology, almost no rigorous human clinical evidence, and a marketing footprint enormously larger than the science supports. Its use in humans is, in effect, an experiment performed by the user on themselves — and the honest answer to "does BPC-157 work?" is that we don't yet have the evidence to know.